Items which should not routinely be prescribed in primary care - dronedarone by all Sub-ICB Locations
Why it matters:
Dronedarone is used for the maintenance of sinus heart rhythm after cardioversion in clinically stable patients with paroxysmal or persistent atrial fibrillation, when alternative treatments are unsuitable (initiated under specialist supervision).
Dronedarone was originally approved to prevent atrial fibrillation from coming back or to lower the heart rate in adults who have had or have non-permanent atrial fibrillation. In September 2011 this indication was restricted to the maintenance of normal heart rhythm in 'persistent' or 'paroxysmal' atrial fibrillation after normal heart rhythm has been restored. This followed a review of data that became available since its authorisation, including data from the PALLAS study.
NICE guidance puts greater emphasis on rate rather than rhythm control and clarifies the place of dronedarone in the treatment pathway.
For guidance on when prescribing may be appropriate in some exceptional circumstances, please see the full NHS England guidance document.
Description: Cost of dronedarone per 1000 patients
Performance: Loading...
Explore:
Tagged as: Cost Saving, Cardiovascular system, NHS England - items which should not routinely be prescribed in primary care, NICE, Safety (or browse all measures)
Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.
View measure for NHS England combined →
Fetching data...